Sequential treatment of recurrent mesenteric desmoid tumor

Bauernhofer, Thomas; Stöger, Herbert; Schmid, Marianne; Smola, M. G.; Gürtl-Lackner, Barbara; Höfler, Gerald; Ranner, G.; Reisinger, Emil C.; Samonigg, Hellmut

doi:10.1002/(sici)1097-0142(19960315)77:6<1061::aid-cncr9>3.0.co;2-k

Cited by 64 publications

(24 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The incidence of aggressive Wbromatosis has been shown to be between two and four cases per million per annum. It constitutes about 3.5% of all Wbrous tissue tumors and 0.003% of all cancers (Bauernhofer et al 1996).…”

Section: Introductionmentioning

confidence: 99%

“…It is utilized in the doses of 40-80 mg, given orally everyday, and the overall response is approximately 50% (Bauernhofer et al 1996), although the results are based on the single-case reports and there is a lack of data from controlled studies. Toremifene is also an antiestrogen, which has a substantial activity against aggressive Wbromatosis after the front-line or second-line therapy with overall response rates of 50 and 33%, respectively (Brooks et al 1992).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Control of aggressive fibromatosis by treatment with imatinib mesylate. A case report and review of the literature

Wcisło

Szarlej-Wcislo

Szczylik

2007

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

Treatment with imatinib mesylate has been a well-accepted therapy for chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST). There have been established four kinases (p210(bcr/abl), c-kit, PDGFR-alfa, PDGFR-beta) suggested as the target for imatinib mesylate. Other potential targets will be discovered as it has lately been determined that M-CSFR kinase activity was blocked by imatinib mesylate. The salvage therapy for aggressive fibromatosis with imatinib mesylate seems to be an attractive opportunity for patients with the advanced disease, whose prior therapy failed.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Control of aggressive fibromatosis by treatment with imatinib mesylate. A case report and review of the literature

Wcisło

Szarlej-Wcislo

Szczylik

2007

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

“…Therefore, a variety of systemic therapeutic approaches have been increasingly investigated and utilized. Responses have been reported using a variety of nonsteroidal anti-inflammatory agents (NSAIDs) [109][110][111], tamoxifen, toremifene, megestrol and other progesterone formulations have been employed successfully for the blockade of sex hormone-dependent cellular proliferation of desmoids [112][113][114][115], interferon [116,117], as well as chemotherapy [118][119][120][121][122]. The data for systemic agents, however, are limited to reports of relatively small series.…”

Section: Aggressive Fibromatosismentioning

confidence: 99%

Imatinib in the treatment of solid tumours

Duffaud

Cesne

2009

Targ Oncol

View full text Add to dashboard Cite

The extraordinary success of imatinib in gastrointestinal stromal tumors (GIST) represents a model for molecularly targeted therapy for other solid tumors. Research is currently going to identify the molecular basis of mechanisms of action and drug resistance. In this article, we review recent advances in the clinical management of patients with GISTs treated with imatinib, but also of patients with dermatofibrosarcoma protuberans, chordoma, aggressive fibromatosis, and some other common solid tumors treated with this drug. We reviewed the knowledge of the molecular mechanisms that are basic to imatinib effects in these tumors.

show abstract

“…Erfolgreiche Therapien wurden für eine Kombination von Sulindac in Kombination mit Warfarin und Vitamin K berichtet. Fallberichte führen Therapieerfolge mit Interferonen (Interferon alpha 2 b, Interferon gamma), LHRH-Analoga (Goserelin), Progesteron, Ascorbinsäure, Prednisolon, Testosteron, Antifibrinolytika (Pirfenidone), Tyrosinkinase-Inhibitoren (ImatinibMesylat) und Hyperthermoradiotherapie an [6,26,38,44,47,69,71]. Weiterhin wird über die isolierte Extremitätenperfusion mit Tumornekrosefaktor-alpha und Melphalan für Rezidiv-DT der Extremitäten berichtet [37].…”

Section: Andere Therapienunclassified

Aktuelle Diagnostik und Therapie von Desmoidtumoren bei Patienten mit familiärer adenomatöser Polyposis – aus chirurgischer Sicht

Jannasch¹,

Evert²,

L³

et al. 2009

Zentralbl Chir

View full text Add to dashboard Cite

Based on a representative selection of relevant references, the aim of this study was to reflect the change of the algorithm in the surgical management of desmoid tumours (DT) in cases of accompanying familial adenomatous polyposis (FAP). Main focus is concerned with the basics of differential treatment, including additional considerations on epidemiology, diagnosis, outcome and follow-up. DT are rare benign tumours that do not metastasise but tend to invade locally. In contrast to the general population, DT in patients with FAP are more common, show a different pattern of tumour sites and cause considerable morbidity and mortality. Most DT occur in the abdominal cavity and account for the majority of serious problems. Genetic disposition and hormonal factors as well as prior surgical trauma are considered causative for the development of DT. Characteristic symptoms are abdominal pain, nausea and vomiting but DT may also present as acute abdomen. CT scan determines localisation and extension of the tumour. Treatment includes various strategies of medication, surgical resection and radiation. Data concerning diagnostic and therapeutic procedures are based on studies with small case series or case reports only. Therefore data from international multicentre studies are necessary for improving the prognosis and developing reliable and stringent guidelines.

show abstract

Sequential treatment of recurrent mesenteric desmoid tumor

Abstract: This study demonstrates long-term regression of a desmoid tumor with combined endocrine therapy using goserelin acetate plus tamoxifen. Tumor progression after 17 months was again stopped by a combination of interferon-gamma and goserelin acetate.

Cited by 64 publications

References 35 publications

Control of aggressive fibromatosis by treatment with imatinib mesylate. A case report and review of the literature

Control of aggressive fibromatosis by treatment with imatinib mesylate. A case report and review of the literature

Imatinib in the treatment of solid tumours

Aktuelle Diagnostik und Therapie von Desmoidtumoren bei Patienten mit familiärer adenomatöser Polyposis – aus chirurgischer Sicht

Contact Info

Product

Resources

About